Recombinant Hepatitis B Virus Core Antigen protein (ab49013)
Description
-
Product name
Recombinant Hepatitis B Virus Core Antigen protein
See all Hepatitis B Virus Core Antigen proteins and peptides -
Biological activity
Reacts strongly with human HBV positive serum. -
Purity
> 95 % SDS-PAGE. -
Expression system
Escherichia coli -
Protein length
Protein fragment -
Animal free
No -
Nature
Recombinant -
-
Amino acids
1 to 183
-
Specifications
Our Abpromise guarantee covers the use of ab49013 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
SDS-PAGE
ELISA
Western blot
-
Form
Liquid -
Additional notes
Reacts strongly with human HBV positive serum. -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
pH: 7.20
Constituents: 0.02% PBS, 50% Glycerol, 0.435% Sodium chloride
General Info
-
Alternative names
- C
- Capsid protein
- core
see all -
Relevance
Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection. The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection. -
Cellular localization
Capsid protein: Virion. Host cytoplasm, hepatocyte nucleus.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (1)
ab49013 has been referenced in 1 publication.
- Toyama M et al. Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. Virus Res 271:197677 (2019). PubMed: 31376401
